Organovo Holdings, Inc. is a clinical-stage biotechnology company. Co. is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). It is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. It uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. We show 46 historical shares outstanding datapoints in our ONVO shares outstanding history coverage, used to compute ONVO market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ONVO market cap history over the course of time is important for investors
interested in comparing ONVO's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ONVO versus a peer is one thing; comparing
ONVO market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ONVO can fluctuate over the course of history.
With this page we aim to empower investors researching ONVO by allowing them to research the ONVO market cap history. |
Free ONVO Email Alerts:
Video: The Importance of Market Cap
